Resource Details


NICE - Guidance on the use of infliximab for Crohn's disease

Author(s)National Institute for Health and Clinical Excellence
AbstractIt is clear from the independent appraisal that Infliximab may provide benefit to some severely ill patients. This guidance is targeted at people who have a severe form of Crohn's disease. This drug should only be prescribed by specialists experienced in treating people with Crohn's disease. This is not a treatment for all people with Crohn's disease. The Committee balanced the known side effects, such as an increased risk of tuberculosis, the effectiveness of infliximab in treating Crohn's and the long- term costs and were clear that they should not recommend widespread use at this time. Patient information is given at Appendix C.
Patient information available at
Date of publishing04/01/2002
Date of last review by us10/26/2005
Bookmark this page Email this page to a friend Print this page



Twitter FeedTwitter Feed